AbbVie Inc.
ABBV
Xếp hạng trong cổ phiếu
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Giá cổ phiếu
$282.96
Đồng bộ lần cuối: 2026-10-19
Vốn hóa thị trường
$500.02B
Thay đổi (1 ngày)
-0.75%
Thay đổi (1 năm)
22.62%
Quốc gia
US
Giao dịch AbbVie Inc. (ABBV)
Danh mục
Healthcare
Tỷ lệ P/S của AbbVie Inc. (ABBV)
Tỷ lệ P/S vào February 2026 TTM: 6.69
Theo các báo cáo tài chính và giá cổ phiếu mới nhất của AbbVie Inc., tỷ lệ P/S hiện tại (TTM) là 6.69. Vào cuối năm 2026, công ty có P/S là 0.
Lịch sử tỷ lệ P/S của AbbVie Inc. từ 2026 đến 2026
Tỷ lệ P/S vào cuối mỗi năm
| Năm | Tỷ lệ P/S | Thay đổi |
|---|---|---|
| Không đủ dữ liệu cho ngày được cung cấp. | ||
Tỷ lệ P/S của các công ty tương tự hoặc đối thủ cạnh tranh
| Công ty | Tỷ lệ P/S | Chênh lệch Tỷ lệ P/S | Quốc gia |
|---|---|---|---|
| 14.32 | 114.06% |
US
|
|
| 6.16 | -7.92% |
US
|
|
| 5.48 | -18.06% |
US
|
|
| 4.66 | -30.37% |
CH
|
|
| 5.52 | -17.48% |
CH
|
